Trial Profile
Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2013
Price :
$35
*
At a glance
- Drugs Sagopilone (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2012 Planned End Date changed from 1 Nov 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 02 May 2012 Planned end date changed from 1 Jul 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.